Enjaymo® (Sutimlimab-jome) - CAM 960HB
Background
FDA-Approved Indication: Enjaymo (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). Enjaymo is a humanized monoclonal antibody that selectively inhibits complement protein C1s, thereby preventing activation of the classical complement pathway responsible for hemolysis in CAD.
Policy (Criteria)
Initial Authorization Criteria
Enjaymo may be considered medically necessary when all of the following criteria are met:
- Diagnosis of Cold Agglutinin Disease (CAD) based on ALL of the following:
- Presence of chronic hemolysis (e.g., bilirubin level above the normal reference range, elevated lactate dehydrogenase [LDH], decreased haptoglobin, increased reticulocyte count)
- Positive polyspecific direct antiglobulin test (DAT)
- Monospecific DAT strongly positive for C3d
- Cold agglutinin titer greater than or equal to 64 measured at 4°C
- Direct antiglobulin test (DAT) result for Immunoglobulin G (IgG) of 1+ or less
- Patient does not have cold agglutinin syndrome secondary to other factors, including but not limited to:
- Overt hematologic malignancy
- Primary immunodeficiency
- Active infection
- Rheumatologic disease
- Systemic lupus erythematosus (SLE)
- Other autoimmune disorders
- Baseline hemoglobin level less than or equal to 10.0 g/dL
- One of the following:
- Prescribed dose will not exceed 6,500 mg intravenously on Day 0, Day 7, and every 14 days thereafter for patients weighing 39 kg to less than 75 kg OR Prescribed dose will not exceed 7,500 mg intravenously on Day 0, Day 7, and every 14 days thereafter for patients weighing 75 kg or greater
- Prescribed by or in consultation with a hematologist
Authorization Duration: 6 months
Reauthorization Criteria
Enjaymo may be reauthorized when all of the following criteria are met:
- Documentation of a positive clinical response to therapy evidenced by ALL of the following:
- The patient has not required any blood transfusions after the first 5 weeks of therapy with Enjaymo
- Hemoglobin level greater than or equal to 12 g/dL OR hemoglobin increased by greater than or equal to 2 g/dL from baseline
- Continued clinical benefit as evidenced by one or more of the following:
- Sustained improvement or stabilization of hemoglobin levels
- Reduction in markers of hemolysis (e.g., bilirubin, LDH, reticulocyte count)
- Reduction in fatigue or CAD-related symptoms
- Reduction in transfusion requirements compared with pre-treatment baseline
- Avoidance of CAD-related hospitalizations or acute complications
- One of the following:
- Prescribed dose does not exceed 6,500 mg every 14 days for patients weighing 39 kg to less than 75 kg OR Prescribed dose does not exceed 7,500 mg every 14 days for patients weighing 75 kg or greater
- Prescribed by or in consultation with a hematologist
Authorization Duration: 12 months
References
- Sanofi. ENJAYMO (sutimlimab-jome) Prescribing Information. Revised 2025.
- U.S. Food and Drug Administration (FDA). ENJAYMO (sutimlimab-jome) Biologics License Application Approval Letter. February 2022.
- Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in Cold Agglutinin Disease. New England Journal of Medicine. 2021;384(14):1323-1334.
- Barcellini W, Röth A, D'Sa S, et al. Results of the Phase 3 CARDINAL Trial of Sutimlimab in Patients with Cold Agglutinin Disease. Blood. 2021.
- Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in Patients with Cold Agglutinin Disease Without Recent Transfusion History (CADENZA Trial). Blood. 2022.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: B-Cell Lymphomas and Related Disorders. Current version.
- Berentsen S. How I Manage Cold Agglutinin Disease. Blood. 2021;137(10):1295-1303.
- UpToDate. Cold Agglutinin Disease: Clinical Features, Diagnosis, and Treatment. Current literature review.
Coding Section
| Code |
Number |
Description |
| HCPCS |
J1302 |
Injection, sutimlimab-jome, 10 mg; 1 billable unit = 10 mg |
| ICD-10 |
D59.12 |
Cold autoimmune hemolytic anemia |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2026 Forward
| 10/01/2026 |
New Policy |